---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-25-017369"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:19:46.501197+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tonix Q3 2025 net loss widens to $32M; cash $190.1M; Tonmya launch in November

## Summary
- Net product revenue $3.3M (up from $2.8M YoY) from Zembrace/Tosymra sales.
- Net loss $32.0M ($3.59 per share) vs $14.2M ($22.68 per share) in Q3 2024; SG&A surged to $25.7M on Tonmya launch prep.
- Cash and equivalents $190.1M (Dec 2024: $98.8M); cash runway into Q1 2027 including $34.7M from Q4 2025 equity offerings.
- Tonmya (fibromyalgia) launch in November 2025; 90 sales reps in field; WAC established; payer formulary placement for Tosymra in 2026.
- Tonix in-licensed TNX-4800 (Lyme disease mAb) and announced Phase 2 collaboration for TNX-1500 (kidney transplant).

## SEC filing metadata
- accession: 0001999371-25-017369
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937125017369/0001999371-25-017369-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937125017369/tnxp-8k_111025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-25-017369
- JSON: https://secwatch.observer/filing/0001999371-25-017369.json
- Plain text: https://secwatch.observer/filing/0001999371-25-017369.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.